EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world evaluation of safety and efficacy of AHCL systems in young children with type 1 diabetes: a 1-year assessment

Daniele Franzone, Giordano Spacco, Andrea Piano, Giulia Siri, Giacomo Tantari, Giuseppe d'Annunzio, Maria Grazia Calevo, Mohamad Maghnie, Nicola Minuto, Marta Bassi

Frontiers in Endocrinology · 26.06.2025 · 16

DOI: 10.3389/fendo.2025.1590964 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Endocrinology, online erschienen am 26.06.2025. Verfasst von Daniele Franzone und 9 weiteren Autor:innen. Beteiligte Einrichtung: DINOGMI (Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health), University of Genoa, Genoa, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin, Insulin Infusion Systems, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims Management of Type 1 Diabetes (T1D) in young children is challenging. A poor glycaemic control during the first years of disease increases the risk of microvascular complications. Moreover, hyperglycaemia and glucose variability have a negative effect on the brain development. Advanced hybrid closed loop (AHCL) systems demonstrated to improve glycaemic control in adolescents and adults with T1D although data on younger children are limited. The aim of the study was to evaluate the safety and the effectiveness of AHCL systems’ off-label use in children aged less than 7 years.

Methods

A retrospective single-center study on T1D patients aged less than 7 years using AHCL systems was conducted. Glycated hemoglobin (HbA1c) values, Continuous Glucose Monitoring (CGM) and insulin requirement data were collected at T0 (AHCL starting), T1 (1-month), T2 (3-months) and T3 (1-year).

Results

41 patients were included in the study. No episode of severe hypoglycaemia occurred. Three patients experienced an episode of ketoacidosis (DKA) due to insulin delivery set occlusion. During the 12-months study period, an improvement in HbA1c value (7.50 vs 6.59%, p<0.001), Time in Range (TIR, +10.21%, p<0.001) and Time in Tight Range (TITR, +7.56%, p=0.003) were observed, with a reduction in time in hyperglycaemia and without an increase in time in hypoglycaemia. The AHCL use increased insulin requirement at 12-months, especially in bolus doses (p<0.001).

Conclusions

Although AHCL systems are not currently approved for this age group, we have demonstrated their safety and efficacy in children under 7 years with T1D. The use of these systems resulted in significant improvement in glycaemic control without increasing the risk of hypoglycaemia. The impact of early glycaemic control on brain development during the first years of life may support the early introduction of AHCL systems in very young children with T1D. It is essential to gather data that could support the approval of these systems for use in younger age groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1InsulinInsulin Infusion SystemsHypoglycemic AgentsGlycemic ControlHumansFemaleMaleRetrospective StudiesChild, PreschoolBlood GlucoseChildGlycated HemoglobinInfantBlood Glucose Self-MonitoringHypoglycemiaFollow-Up StudiesTreatment Outcome

Stichwörter der Autor:innen

AHCL (advanced hybrid closed loop)AID (automated insulin delivery)off-labeltoddlerstype 1 diabetes

Substanzen

Blood GlucoseInsulinHypoglycemic AgentsGlycated Hemoglobinhemoglobin A1c protein, human

Autor:innen und Institutionen

  • DINOGMI (Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health), University of Genoa, Genoa, Italy.
  • Department of Pediatrics and Neonatology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini, Savona, Italy.
  • Pediatric Clinic, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini, Genoa, Italy.
  • Biostatistics Unit, Scientific Directorate, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini, Genoa, Italy.

Zitieren

APA

Franzone, D., Spacco, G., Piano, A., Siri, G., Tantari, G., d'Annunzio, G., Calevo, M. G., Maghnie, M., Minuto, N., & Bassi, M. (2025). Real-world evaluation of safety and efficacy of AHCL systems in young children with type 1 diabetes: a 1-year assessment. Frontiers in Endocrinology, 16. https://doi.org/10.3389/fendo.2025.1590964

Vancouver

Franzone D, Spacco G, Piano A, Siri G, Tantari G, d'Annunzio G, et al. Real-world evaluation of safety and efficacy of AHCL systems in young children with type 1 diabetes: a 1-year assessment. Frontiers in Endocrinology. 2025;16. doi:10.3389/fendo.2025.1590964

BibTeX
@article{Franzone2025,
  author = {Franzone, Daniele and Spacco, Giordano and Piano, Andrea and Siri, Giulia and Tantari, Giacomo and d'Annunzio, Giuseppe and Calevo, Maria Grazia and Maghnie, Mohamad and Minuto, Nicola and Bassi, Marta},
  title = {Real-world evaluation of safety and efficacy of AHCL systems in young children with type 1 diabetes: a 1-year assessment},
  journal = {Frontiers in Endocrinology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fendo.2025.1590964}
}
Kostenlos starten →